Q-omics provides the consensus-scored RPL7P13 profile across patient tissues and cancer cell-line models. RPL7P13 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPL7P13 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, RPL7P13 RNA expression shows 9,659 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, COAD, and UVM as cancer lineages where RPL7P13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7P13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7P13 survival associations across molecular data types. RPL7P13 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7P13 RNA expression–survival associations across cancer types. High RPL7P13 expression shows unfavorable associations in LIHC, UVM and OV, but favorable associations in SKCM, THYM and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RPL7P13 RNA expression.
This table summarizes RPL7P13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7P13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7P13 shows lower tumor expression in BRCA and higher tumor expression in COAD, LIHC, STAD, READ and CHOL. The COAD box plot shows higher RPL7P13 RNA expression in tumor versus normal tissue (log2 FC = +0.232, t-test p < 0.001).
This table shows molecular features associated with RPL7P13 in patient tissues and cancer cell lines. In patient samples, RPL7P13 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
